To augment MP-OVA/Riboxxim mediated tumor retardation, four accessory systemic injections of an immune checkpoint inhibitory anti-CTLA-4 monoclonal antibody (mAb) was added to the therapeutic regimen (Fig. 6a). The gene discussed is CTLA4; the disease is neoplasm.